Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.

MLA

Mancinelli, Chiara Rosa, et al. “Switching to Ocrelizumab in RRMS Patients at Risk of PML Previously Treated with Extended Interval Dosing of Natalizumab.” Multiple Sclerosis Journal, vol. 27, no. 5, Apr. 2021, pp. 790–94. EBSCOhost, https://doi.org/10.1177/1352458520946017.

APA

Mancinelli, C. R., Scarpazza, C., Cordioli, C., De Rossi, N., Rasia, S., Turrini, M. V., & Capra, R. (2021). Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab. Multiple Sclerosis Journal, 27(5), 790–794. https://doi.org/10.1177/1352458520946017

Chicago

Mancinelli, Chiara Rosa, Cristina Scarpazza, Cinzia Cordioli, Nicola De Rossi, Sarah Rasia, Maria Vittoria Turrini, and Ruggero Capra. 2021. “Switching to Ocrelizumab in RRMS Patients at Risk of PML Previously Treated with Extended Interval Dosing of Natalizumab.” Multiple Sclerosis Journal 27 (5): 790–94. doi:10.1177/1352458520946017.